Maclean D B, Jackson I M
Baillieres Clin Endocrinol Metab. 1988 Nov;2(4):835-68. doi: 10.1016/s0950-351x(88)80021-1.
Over the past twenty years, each of the five major hypothalamic releasing or release-inhibiting hormones has been sequenced and its gene structure determined. With the use of molecular biological techniques, such as in situ hybridization, Northern blot analysis or gene constructs for in vitro or in vivo transfection studies--together with 'traditional' neuroendocrinological techniques, such as immunocytochemistry, radio-immunoassay and portal vessel cannulation--investigators have been able to address major issues in neuroendocrine regulation. Several common themes have emerged: messenger RNA expression is uniformly present in neurons that are immunopositive for the specific hypothalamic hormone. Steady state RNA levels within the hypophysiotropic neuron groups are either increased or reduced by changes in specific target hormones that conform to predictions based on previous physiological data. Regulation by the requisite peripheral hormone is exquisitely anatomically specific and is not evident in extrahypophysiotropic regions. Determining the receptor or genetic basis of this specificity is a major focus of current research. Clarifying the apparently lesser role of afferent neural pathways to the hypothalamus in regulating releasing hormone mRNA levels is also an important challenge. Clinically, the measurement of levels of releasing hormones in the peripheral circulation appears to be of limited usefulness, except in rare cases of ectopic GRH or CRH secretion. For diagnostic purposes, each of the releasing hormones has specific utility in amplifying the release and measurement of pituitary hormones, both to clarify the overall physiological activity of the hypothalamic-pituitary-target hormone axis and to further define the anatomic locus of any underlying disturbance. The usefulness of somatostatin as a diagnostic tool is presently limited, but the development of SS receptor antagonists might have significant impact in future clinical investigation. The molecular mechanisms of action of the hypothalamic hormones have been separated into those whose receptor-effector function is mediated by the cAMP-adenylate cyclase pathway(s), GRH and CRH, and those working through the phosphoinositide-protein kinase C cascade, GnRH and TRH. Each of the hormone receptors is coupled to intermediary G proteins, somatostatin uniquely to the inhibitory subclass. The mechanisms responsible for sensitization (priming) or desensitization are not fully understood but are presumably related to receptor down regulation and protein phosphorylation.(ABSTRACT TRUNCATED AT 400 WORDS)
在过去的二十年里,五种主要的下丘脑释放或释放抑制激素均已完成测序,并确定了其基因结构。借助分子生物学技术,如原位杂交、Northern印迹分析或用于体外或体内转染研究的基因构建体,再结合“传统的”神经内分泌技术,如免疫细胞化学、放射免疫测定和门静脉插管法,研究人员得以解决神经内分泌调节中的重大问题。现已出现几个共同的主题:信使核糖核酸(mRNA)表达一致存在于对特定下丘脑激素呈免疫阳性的神经元中。促垂体神经元组内的稳态RNA水平会因特定靶激素的变化而升高或降低,这些变化符合基于先前生理学数据的预测。必需外周激素的调节在解剖学上具有高度特异性,在促垂体区以外的区域并不明显。确定这种特异性的受体或遗传基础是当前研究的主要重点。阐明传入下丘脑的神经通路在调节释放激素mRNA水平方面明显较小的作用也是一项重要挑战。在临床上,测量外周循环中释放激素的水平似乎用处有限,除非在罕见的异位促性腺激素释放激素(GRH)或促肾上腺皮质激素释放激素(CRH)分泌病例中。出于诊断目的,每种释放激素在放大垂体激素的释放和测量方面都有特定用途,既能阐明下丘脑 - 垂体 - 靶激素轴的整体生理活性,又能进一步确定任何潜在紊乱的解剖学部位。目前,生长抑素作为诊断工具的用途有限,但生长抑素受体拮抗剂的开发可能会对未来的临床研究产生重大影响。下丘脑激素的分子作用机制已分为两类,一类其受体 - 效应器功能由环磷酸腺苷 - 腺苷酸环化酶途径介导,如GRH和CRH;另一类通过磷脂酰肌醇 - 蛋白激酶C级联反应起作用,如促性腺激素释放激素(GnRH)和促甲状腺激素释放激素(TRH)。每种激素受体都与中间G蛋白偶联,生长抑素则独特地与抑制性亚类偶联。负责致敏(启动)或脱敏的机制尚未完全了解,但可能与受体下调和蛋白质磷酸化有关。(摘要截选至400字)